Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: A novel approach for tailored immunosuppressive therapy
- 1 December 2005
- journal article
- clinical trial
- Published by Elsevier BV in Kidney International
- Vol. 68 (6), 2593-2598
- https://doi.org/10.1111/j.1523-1755.2005.00731.x
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Long-Term Benefits with Sirolimus-Based Therapy after Early Cyclosporine WithdrawalJournal of the American Society of Nephrology, 2004
- Blockage of 2-Deoxy-d-Ribose-Induced Angiogenesis with Rapamycin Counteracts a Thymidine Phosphorylase-Based Escape Mechanism Available for Colon Cancer under 5-Fluorouracil TherapyClinical Cancer Research, 2004
- Sirolimus: a ten-year perspectiveTransplantation Proceedings, 2004
- Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear CellsCancer Research, 2004
- A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipientsTransplantation, 2003
- Ribosomal S6 Kinase Signaling and the Control of TranslationExperimental Cell Research, 1999
- Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progressionClinical Biochemistry, 1998